Scholarlink

<p>The recent breakthroughs in KRAS inhibition have converted a previously “undruggable” oncogene into a viable therapeutic target. However, the inconsistency in clinical responses across tumor types highlights that mutation alone is not sufficient to predict therapeutic outcomes. This Perspective introduces a multidimensional framework that uniquely integrates KRAS mutational status with tissue, co-mutation, signaling, and immune context to inform rational trial design, predictive biomarker development, and the advancement of KRAS-targeted therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Context defines precision: rethinking KRAS inhibition in oncology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Serena Marchiò

摘要

The recent breakthroughs in KRAS inhibition have converted a previously “undruggable” oncogene into a viable therapeutic target. However, the inconsistency in clinical responses across tumor types highlights that mutation alone is not sufficient to predict therapeutic outcomes. This Perspective introduces a multidimensional framework that uniquely integrates KRAS mutational status with tissue, co-mutation, signaling, and immune context to inform rational trial design, predictive biomarker development, and the advancement of KRAS-targeted therapies.